ETF Components for MNTL - Tema Neuroscience and Mental Health ETF


Below is a list of stocks held by this ETF. We only list holdings in the same market. If this is a global ETF, there may be additional components other than those listed here.

Holdings

Symbol Grade Price % Change Allocation
VRTX D -0.76 8.52
LLY F -1.50 4.89
REGN F -0.31 4.53
ALNY D 0.33 4.52
ARGX A -0.09 4.48
NBIX C -0.33 4.14
CRNX B -0.56 3.88
TEVA C 0.41 3.72
BIIB F -0.20 3.57
SYK A 0.30 3.08
MDT D 0.38 2.90
IONS F -0.40 2.66
ITCI B -0.29 2.54
DNLI D -0.23 2.26
XENE D 0.64 2.25
CPRX C -0.33 2.22
RNA C -1.23 2.14
DAWN D -1.10 2.10
AXSM B 0.48 1.96
SRPT F -0.70 1.88
JAZZ B 1.31 1.81
DXCM C -0.52 1.80
ACAD C -2.86 1.61
NTLA F 5.04 1.56
ALKS C 0.14 1.47
IMVT F 0.67 1.46
PEN B -0.58 1.24
PTCT B 0.66 1.18
DYN D -1.23 1.17
SRRK B -0.04 1.09
PRTA F -0.55 1.03
OPCH F -0.30 0.96
ACHC F -2.30 0.88
VYGR F -1.12 0.87
ALEC F -1.10 0.67
QTRX F 0.00 0.57
ARVN F 0.63 0.46

Recent News for Tema Neuroscience and Mental Health ETF & its Holdings

Date Stock Title
Nov 21 JAZZ Zymeworks, Jazz Pharmaceuticals Receive FDA's Accelerated Approval for Ziihera to Treat Biliary Tract Cancer
Nov 21 JAZZ Jazz and Zymeworks announce FDA approval of cancer therapy Ziihera
Nov 21 LLY Eli Lilly, Verge announce milestones in ALS collaboration
Nov 21 TEVA Teva Pharmaceutical (TEVA): The Global Leader in Affordable Medicine Under $25
Nov 21 LLY Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop
Nov 21 JAZZ Jazz Pharmaceuticals Announces U.S. FDA Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)
Nov 20 LLY Jim Cramer on Eli Lilly and Company (LLY): ‘I’m Kind Of Blown Away’
Nov 20 DAWN Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & Development
Nov 20 PEN Penumbra, Inc. to Present at the Piper Sandler 36th Annual Healthcare Conference
Nov 20 MDT Medtronic plc (MDT): A Key Player in Ken Griffin’s Portfolio with Steady Growth
Nov 20 LLY Eli Lilly in pact with Chinese biotech for novel weight loss therapy
Nov 20 BIIB Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside
Nov 20 LLY More companies covering weight loss drugs for their employees
Nov 20 LLY Weight loss drug makers want more insurance plans to cover Wegovy and Zepbound
Nov 20 MDT Medtronic reports rise in Q2 FY 2025 net income to $1.27bn
Nov 20 ACHC Morgan Stanley lists hedge funds’ largest Q3 ownership increases in Russell 1000 stocks
Nov 20 LLY China-based biotech Laekna teams up with Lilly to develop muscle preserving obesity drug
Nov 20 MDT Healing People and Planet: New Impact Report Outlines How Medtronic Is Shaping the Future of Health
Nov 20 SYK Stryker Stock May Gain From Oculan Lighting Platform's Launch
Nov 20 MDT Medtronic receives FDA clearance for new InPen app
Under normal circumstances, the Tema Neuroscience and Mental Health ETF seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in neuroscience and mental health companies. A company is generally considered to be a neuroscience or mental health company that derives at least 50% of revenues from neuroscience or neurology-related diseases, or mental health. The fund is non-diversified.
Neuroscience Neurophysiology Neurology Nervous System
Back to the Main MNTL Page...